Although use of potent novel diabetes drugs such as SGLT-2 inhibitors and GLP-1 receptor agonists is still limited in older adults for primary cardiovascular prevention,40 model recalibration may be necessary in the future if a significant increase in their uptake is observed. This evidence concerns the gene GLP1R and diabetes mellitus.